ABVC BioPharma (ABVC) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

ABVC · Stock Price

USD 1.10-0.26 (-19.12%)

Market Cap: $28.2M

Historical price data

Overview

ABVC BioPharma's mission is to develop and commercialize novel therapeutics derived from botanical compounds and synthetic molecules. Its key achievements include advancing multiple assets into clinical trials for conditions like Major Depressive Disorder (MDD), ADHD, and various solid tumors. The company's strategy leverages both internal R&D and external academic collaborations to navigate the capital-intensive drug development pathway, aiming to create value through clinical milestones and potential partnerships.

Oncology/HematologyNeurologyOphthalmology

Technology Platform

A dual-source development strategy focusing on therapeutic candidates derived from botanical compounds and synthetic small molecules, rather than a single proprietary technology platform.

Opportunities

ABVC's pipeline targets large, high-value markets in depression, ADHD, and lethal cancers like pancreatic cancer, where any clinical success would be highly impactful.

Its dual-source strategy offers a diversified approach to novel drug discovery, potentially leading to unique mechanisms of action.

Risk Factors

The company faces extreme clinical development risk, with a high probability of trial failure, coupled with severe financial risk due to its pre-revenue status and urgent need for dilutive capital raises.

It also competes in crowded markets against much larger, better-funded entities.

Competitive Landscape

ABVC competes in neurology against pharma giants and a wave of biotech innovation in psychedelics and novel modulators. In oncology, it faces dominant players in immunotherapy and targeted therapy. Its strategy is to identify niche biological hypotheses and prove concept to attract partnership interest from larger players.

More companies in United States →